5
Venkat Pharma
532093 BSE
Venkat Pharma
Healthcare BSE: 532093 Pharmaceuticals & Biotechnology
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Stock is trading at 0.34 times its book value
Weaknesses
2- Company has low interest coverage ratio.
- Company might be capitalizing the interest cost
Growth Rate
Net Income Growth
33% higher than
3Y
Quarterly Results
| Particulars | Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.01 | 0 | 0.01 | 0 | 0 | 0.01 | 0.01 | 0 |
| Operating Profit | -0.01 | 0 | -0.01 | 0 | 0 | -0.01 | -0.01 | 0 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.01 | 0 | -0.01 | 0 | 0 | -0.01 | -0.01 | 0 |
| Tax % | 0% | — | 0% | — | — | 0% | 0% | — |
| Net Profit | -0.01 | 0 | -0.01 | -0.01 | 0 | -0.01 | -0.01 | 0 |
| EPS in Rs | -0.02 | 0 | -0.02 | -0.02 | 0 | -0.02 | -0.02 | 0 |
Profit & Loss
| Particulars | Jun 2006 15m | Mar 2007 9m | Mar 2008 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 13.84 | 0.63 | 1.05 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 12.56 | 6.92 | 2.39 | 0.2 | 0.04 | 0.02 | 0.03 | 0.02 |
| Operating Profit | 1.28 | -6.29 | -1.34 | -0.2 | -0.04 | -0.02 | -0.03 | -0.02 |
| OPM % | 9.25% | -998.41% | -127.62% | — | — | — | — | — |
| Other Income | 0 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 |
| Interest | 2.03 | 0.25 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.28 | 0.13 | 0.06 | 0.04 | 0.02 | 0.02 | 0.02 | 0 |
| PBT | -1.03 | -6.67 | -1.39 | -0.24 | -0.06 | -0.04 | -0.05 | -0.02 |
| Tax % | -5.83% | 0.15% | 0% | 4.17% | 0% | 0% | 0% | — |
| Net Profit | -0.97 | -6.68 | -1.39 | -0.25 | -0.06 | -0.04 | -0.04 | -0.02 |
| EPS in Rs | -1.94 | -13.39 | -2.79 | -0.5 | -0.12 | -0.08 | -0.08 | -0.04 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Jun 2006 | Mar 2007 | Mar 2008 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 |
| Reserves | 1.4 | -5.28 | -6.67 | -7.38 | -7.44 | -7.48 | -7.53 |
| Borrowings | 15.63 | 16.2 | 16.19 | 16.19 | 16.19 | 19.2 | 19.22 |
| Other Liabilities | 7.66 | 4.48 | 4.67 | 4.47 | 4.39 | 1.42 | 1.31 |
| Total Liabilities | 29.68 | 20.39 | 19.18 | 18.27 | 18.13 | 18.13 | 17.99 |
| Fixed Assets | 1.21 | 1.08 | 1 | 0.92 | 0.89 | 0.87 | 0.85 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 28.47 | 19.31 | 18.18 | 17.35 | 17.24 | 17.26 | 17.14 |
| Total Assets | 29.68 | 20.39 | 19.18 | 18.27 | 18.13 | 18.13 | 17.99 |
Cash Flow
| Particulars | Jun 2006 | Mar 2007 | Mar 2008 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 |
|---|---|---|---|---|---|---|---|
| Operating | — | — | — | 0 | 0 | -0.01 | 0 |
| Investing | — | — | — | 0 | 0 | 0 | 0 |
| Financing | — | — | — | 0 | 0 | 0 | 0 |
| Net Cash Flow | — | — | — | 0 | 0 | -0.01 | 0 |
| Free Cash Flow | — | — | — | 0 | 0 | -0.01 | 0 |
| CFO/OP | — | — | — | 0 | 0 | 50 | 0 |
Ratios
| Particulars | Jun 2006 | Mar 2007 | Mar 2008 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 483 | 8,633 | 4,599 | — | — | — | — |
| Inventory Days | 181 | 394 | 890 | — | — | — | — |
| Days Payable | 182 | 652 | 1,777 | — | — | — | — |
| Cash Conversion Cycle | 482 | 8,374 | 3,713 | — | — | — | — |
| Working Capital Days | 540 | 8,488 | 4,672 | — | — | — | — |
| ROCE % | — | — | -9.14% | — | -0.44% | -0.26% | -0.3% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Venkat Pharma insights
42 extracted metrics + investor summaries across FY07–FY26.
Documents
1
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
26 Feb - -Analyst / Institutional Investor Meeting scheduled on February 27, 2026. 26 Feb - -Analyst / Institutional Investor Meeting scheduled on February 27, 2026.
2
Announcement under Regulation 30 (LODR)-Allotment
23 Feb - Allotment of 43,000 NCDs totaling INR430 crore to ADB; 7.79% coupon; 7-year tenure (23-Feb-2026 to 23-Feb-2033). 23 Feb - Allotment of 43,000 NCDs totaling INR430 crore to ADB; 7.79% coupon; 7-year tenure (23-Feb-2026 to 23-Feb-2033).
3
Announcement under Regulation 30 (LODR)-Change in Directorate
22 Feb - Rajendra Mutha re-appointed Executive Chairman for five years from April 26, 2026 to April 25, 2031, subject to postal ballot. 22 Feb - Rajendra Mutha re-appointed Executive Chairman for five years from April 26, 2026 to April 25, 2031, subject to postal ballot.
4
Update Of Meeting Held On February 22, 2026.
22 Feb - Re-appointment of Rajendra Mutha as Executive Chairman from April 26, 2026 to April 25, 2031 (subject to shareholder approval). 22 Feb - Re-appointment of Rajendra Mutha as Executive Chairman from April 26, 2026 to April 25, 2031 (subject to shareholder approval).
5
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
11 Feb - Transcript of Earning call held on February 06, 2026 at 12:30 Hrs. (IST). 11 Feb - Transcript of Earning call held on February 06, 2026 at 12:30 Hrs. (IST).
Frequently Asked Questions about Venkat Pharma
What does Venkat Pharma Ltd do?
Venkat Pharma Ltd is engaged in the manufacture and sale of finished dosages of pharmaceutical products in India.
Where is Venkat Pharma Ltd (532093) listed?
Venkat Pharma Ltd trades under code 532093 on the BSE.
Which sector does Venkat Pharma Ltd belong to?
Venkat Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Venkat Pharma Ltd is engaged in the manufacture and sale of finished dosages of pharmaceutical products in India.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/532093.md for Venkat Pharma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.